Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
1. Among patients with type 2 diabetes in Hong Kong, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) can reduce ...
Tag: SGLT2i
Empagliflozin use is associated with slower progression of chronic kidney disease
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...
Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease
1. Dapagliflozin reduced the risk of hospitalization in patients with chronic kidney disease (CKD) with and without type 2 diabetes ...
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
